CANOA: Clopidogrel Reduces Migraine After ASD ClosureCANOA: Clopidogrel Reduces Migraine After ASD Closure

The study provides definitive data that dual antiplatelet therapy leads to fewer migraines after transcatheter closure of an atrial septal defect, the lead author says. Heartwire from Medscape
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news

Related Links:

Authors: Kato Y, Hayashi T, Kato R, Takao M Abstract Catheter ablation for atrial fibrillation creates an iatrogenic atrial septal defect by transseptal puncture, which may produce a transient right-to-left shunt. We encountered a 44-year-old man who presented with de novo migraine-like headache after cryoballoon ablation for atrial fibrillation. On reviewing the literature, we found additional cases in which migraine-like headache occurred within one week after the procedure and spontaneously within three months. We should recognize migraine-like headache as a potential complication of catheter ablation. PMID:...
Source: Internal Medicine - Category: Internal Medicine Tags: Intern Med Source Type: research
​BY GORDON MURPHY, PA-C, MPHThe patient was blue, her primary care physician noted. Quite literally, in fact.The 38-year-old woman had sought care for a recurrent urinary tract infection, and that's when her primary care physician found her pulse oximetry to be 74%. He was concerned about hypoxia and asked us to evaluate her.The patient reported taking an SSRI for anxiety and having a hormone-eluting IUD. She had previously had a Roux-en-Y gastric bypass. She said she had a headache, but had been instructed not to take NSAIDs. She said she had just finished a course of Cipro for her UTI, but continued to be symptomatic w...
Source: The Case Files - Category: Emergency Medicine Tags: Blog Posts Source Type: research
We report a 16 years-old male who required surgical explantation of the device 6 years after closure because of debilitating headaches. He had grade I reaction to nickel following skin testing. Intraoperatively, the device had not fully endothelialised. Immediately after surgery, his headaches completely resolved. Long-term Nickel allergy may cause severe migraine, secondary to lack of endothelialisation of a device. Extreme cases may require surgical removal of the device.
Source: The Annals of Thoracic Surgery - Category: Cardiovascular & Thoracic Surgery Source Type: research
We report a 16 years-old male who required surgical explantation of the device 6 years after closure because of debilitating headaches. He had grade I reaction to nickel following skin testing. Intraoperatively, the device had not fully endothelialised. Immediately after surgery, his headaches completely resolved. Long-term Nickel allergy may cause severe migraine, secondary to lack of endothelialisation of a device. Extreme cases may require surgical removal of the device. PMID: 30794784 [PubMed - as supplied by publisher]
Source: The Annals of Thoracic Surgery - Category: Cardiovascular & Thoracic Surgery Authors: Tags: Ann Thorac Surg Source Type: research
Authors: Madhkour R, Wahl A, Praz F, Meier B Abstract INTRODUCTION: The patent foramen ovale (PFO) is a common anatomical variant in humans (prevalence 25%). Most often asymptomatic, it may engender paradoxically embolic strokes, myocardial infarctions, or visceral or peripheral ischemia. It is causatively related to migraine, positional or exertional hypoxemia with dyspnea, diving incidents, high altitude edema, and sleep apnea. Percutaneous closure of atrial septal defects was first performed in the seventies. A dedicated PFO occluder (Amplatzer PFO Occluder) was first used on September 10, 1997 by Kurt Amplatz a...
Source: Expert Review of Medical Devices - Category: Medical Devices Tags: Expert Rev Med Devices Source Type: research
W.L. Gore &Associates has received FDA approval to expand the indication of the Gore Cardioform Septal Occluder to reduce the risk of recurrent ischemic stroke in patients. The device treats patients through the closure of patent foramen ovale (PFO). Cardioform’s previous indication was for the closure of atrial septal defects that are up to 17mm in size. Gore’s Structural Heart Leader, Jake Goble said Cardioform has the potential to redefine stroke prevention. Goble began working for Gore in 2007. It was around that time the company began to explore the possibility of having the Cardioform focus on stroke ...
Source: MDDI - Category: Medical Devices Authors: Tags: Cardiovascular Source Type: news
Int J Angiol DOI: 10.1055/s-0038-1626718Device therapy is a viable alternative to open heart surgery in the management of intracardiac defects. The Amplatzer septal occluder (ASO) is one such device that has been adapted to close a wide variety of cardiac defects with few complications and a high success rate. This is a retrospective review of all the patients who received the ASO between 2012 and 2016 at the University of Kentucky. In total, 169 patients underwent percutaneous closure of a septal defect with Amplatzer during the timeframe studied, and of those, 91% received the device for an atrial septal defect or patent...
Source: International Journal of Angiology - Category: Cardiology Authors: Tags: Original Article Source Type: research
We present an unusual case where symptoms of headache and chest pain persisted for 3 years following the implantation of a septal occluder device for an atrial septal defect despite endothelialisation of the device. The patient was found to have nickel hypersensitivity on patch testing. Following the removal of the device the patient had complete resolution of headaches and chest pain up to 10 months post‐explantation.
Source: Australasian Journal of Dermatology - Category: Dermatology Authors: Tags: Brief Reports Source Type: research
We present an unusual case where symptoms of headache and chest pain persisted for 3 years following the implantation of a septal occluder device for an atrial septal defect despite endothelialisation of the device. The patient was found to have nickel hypersensitivity on patch testing. Following the removal of the device the patient had complete resolution of headaches and chest pain up to 10 months post-explantation. PMID: 29380348 [PubMed - as supplied by publisher]
Source: The Australasian Journal of Dermatology - Category: Dermatology Authors: Tags: Australas J Dermatol Source Type: research
CONCLUSION: Percutaneous placement of an Amplatzer occluder was safe and effective with use of local anesthesia and fluoroscopy alone. There were no recurrent strokes over>4 years. Migraine relief was reported by>80% of patients. PMID: 29455783 [PubMed - in process]
Source: Indian Heart J - Category: Cardiology Authors: Tags: Indian Heart J Source Type: research
More News: Atrial Septal Defect | Brain | Clopidogrel | Headache | Health | Hole in the Heart | Migraine | Neurology | Neurosurgery | Plavix | Study